Affinity Wealth Management LLC Buys Shares of 303,533 Adaptive Biotechnologies Corporation $ADPT

Affinity Wealth Management LLC purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 303,533 shares of the company’s stock, valued at approximately $4,541,000. Affinity Wealth Management LLC owned approximately 0.20% of Adaptive Biotechnologies at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in Adaptive Biotechnologies by 3.1% in the third quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock worth $349,000 after buying an additional 700 shares during the last quarter. Bouvel Investment Partners LLC lifted its stake in Adaptive Biotechnologies by 2.2% in the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after acquiring an additional 904 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Adaptive Biotechnologies by 3.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock worth $355,000 after acquiring an additional 910 shares in the last quarter. California State Teachers Retirement System grew its position in Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after acquiring an additional 933 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in shares of Adaptive Biotechnologies by 7.6% during the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after purchasing an additional 1,119 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on ADPT. Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research raised their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. JPMorgan Chase & Co. upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies Stock Up 3.2%

Shares of ADPT stock opened at $16.04 on Friday. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76. The firm has a market cap of $2.45 billion, a PE ratio of -40.10 and a beta of 2.18. The stock has a 50 day moving average of $16.86 and a 200-day moving average of $15.37.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies’s revenue was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. As a group, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, CEO Chad M. Robins sold 124,998 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $18.94, for a total transaction of $2,367,462.12. Following the sale, the chief executive officer owned 2,709,241 shares of the company’s stock, valued at approximately $51,313,024.54. This trade represents a 4.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Harlan S. Robins sold 34,668 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $18.60, for a total value of $644,824.80. Following the sale, the insider owned 1,187,644 shares in the company, valued at approximately $22,090,178.40. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,513,196 shares of company stock valued at $26,291,033 in the last three months. Company insiders own 6.40% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.